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Payment (BHP) and Health Care Expenditure (HCE) were more
precise measurements of equity in health care ﬁnance and uti-
lization, respectively. The BHP was deﬁned as the ratio of the
sum of the premium and out-of-pocket spending to disposable
income. We used the 1992–2002 data to examine the following
hypotheses at the individual level, categorized into ﬁve income
quintiles: Hypothesis 1: Equity in BHP and HCE improves after
having the NHI program. Hypothesis 2: Equity in BHP and HCE
deteriorates with recession. We categorized the data into ﬁve
income quintiles. RESULTS: This study conﬁrms the two
hypotheses. NHI can narrow the disparity in medical care equity,
but recession can widen it. We found that the BHP was regres-
sive, while the HCE for the poorest is signiﬁcantly higher than
that for the others. We also found that the recession of 2001 had
a signiﬁcantly greater impact on the poor versus the rich quin-
tile. In conclusion, NHI reform is still an unﬁnished job. CON-
CLUSIONS: The resource allocations need to be rearranged
whenever a recession occurs.
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There is widespread concern over the ability to pay for (“afford-
ability” of) total health care expenditures (THE) rising faster
than gross domestic product (GDP). Current predictions of
future health spending trends suggest, for the U.S. and Germany
alike, that THE growth may exceed GDP growth rates by up to
two-percentage points. OBJECTIVE: To estimate, from a macro-
economic perspective, the extent of future ability to pay, in the
United States and Germany, for THE growth outpacing GDP
growth by two percentage points and its sensitivity to assumed
economic growth rates. METHODS: We assumed the upper
limit of “ability to pay” to be reached once the increase of THE
would fully absorb the growth of GDP, i.e., when non-health
spending would stagnate or commence to decline. Using a math-
ematical model based on this incremental deﬁnition of “afford-
ability”, we conducted one-way and two-way sensitivity analyses
to examine the relationship between “affordable” THE and GDP
growth. RESULTS: Under a base case assumption of real per-
capita GDP growth rates of 1.2 percent per year, both economies
(U.S. and Germany) could afford a two-percentage-point gap
between THE and GDP for the next several decades (United
States: beyond 2050; Germany: beyond 2060). Two-way sensi-
tivity analysis revealed that higher GDP growth rates resulted in
slight increases of this time span only, whereas the time of afford-
able THE growth exhibited high and asymmetric sensitivity to
lower rates of real per-capita GDP growth. CONCLUSION:
Under the assumption of real per-capita GDP growth rates above
one percent annually, societal willingness to pay, not ability to
pay, will determine the extent of future THE growth. Future
funding of health care will be determined by distributive aspects
and the value of health (care), not “affordability”.
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OBJECTIVES: Consumer opinions are important to increase use
of less expensive generic drugs. The objective of this study was
to examine factors that may affect consumer perceptions regard-
ing generic drug substitution practices. METHODS: Data were
collected from consumers ﬁlling prescriptions at 10 Walgreen
stores situated around Houston (N = 1000) by administering a
survey. Factors such as prior drug purchase behavior and role of
pharmacists were measured using four items on a 5-point scale
where 1 = never and 5 = always. Consumer perception about
generic drugs was measured using a semantic differential scale.
A 5-point Likert scale was used to evaluate their perception
regarding drug substitution practices. Demographic data such as
age, gender, education and income were collected and analyzed
to perform descriptive and correlation analyses. RESULTS: A
total of 505 completed surveys were analyzed. The mean age 
was (42.63 3–4 15.8) years with 90.51% being enrolled in the
health plan. Majority were female (62.02%) and fulltime
employees (61.9%). Respondents had a positive attitude towards
generic drugs (3.84 3–4 0.89) and drug substitution practices (3.74
3–4 0.79). The correlation analysis indicated a positive correlation
between consumers *.115 perception regarding drug substitution
practices and prior use of prescription (r = 0.49, p < 0.05) and
non-prescription drugs (r = 0.28, p < 0.05). Although half of the
participants (54%) indicated that they never refused their phar-
macists for substituting with a generic drug, only 11.20% of the
participants indicated being always asked by their pharmacists
for such substitution. CONCLUSIONS: Consumers’ positive
perceptions towards generic drug and generic drug substitution
practices could help drug management strategies by managed
care organizations to reduce health care costs. Pharmacists may
need to be provided incentives to actively promote generic sub-
stitution to consumers.
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OBJECTIVE: Texas, compared to many other state Medicaid
programs, provides relatively unrestricted coverage of OTC med-
ications that are prescribed by a physician to non-institutional-
ized clients. We conducted a descriptive analysis to investigate
utilization and payment trends for this class of drugs.
METHODS: A retrospective analysis of Texas Medicaid paid
prescription claims for OTC medications dispensed during the
ﬁrst three months of 2003 for Fee-For-Service and Primary Care
Case Management clients was conducted. All OTC products
were included in the analyses, with the exception of insulin prod-
ucts, and syringes. The association of a claim for an OTC med-
ication as a result of an actual physician visit was also assessed.
RESULTS: During the study period, there were a total of
609,185 OTC prescription claims (7.1% of total claims)
accounting for $5.1 million in Texas Medicaid payments (1.1%
of total pharmacy program payments). The average payment per
OTC claim was $8.44. Acetaminophen and oral liquid elec-
trolytes, alone, accounted for 50.4% of all claims and 59.8% of
all payments. Children aged two years or less accounted for
50.1% of all OTC medications dispensed and 49.1% of all OTC
payments. A total of 8.8% of all eligible clients aged 18 and
under had at least one paid OTC claim during January 2003.
Pediatricians, alone, prescribed 50.3% of all OTC medications.
We found that 71.1% of the OTC claims were the result of an
actual physician ofﬁce visit. In addition, 84.3% of pharmacy
visits for OTC claims also had a claim for a prescription-only
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product during the same visit. CONCLUSION: Expenditures for
OTC medications within the Texas Medicaid Pharmacy Program
accounted for 1.1% of total program payments. Clients under
the age of 18, especially infants, are the largest beneﬁciary group
of OTC medication coverage within the Texas Medicaid
Program.
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OBJECTIVE: To determine the effect of adding the pharmacy
cost data option to the Adjusted Clinical Groups Predictive
Model (ACG-PM) when estimating future total health care costs.
METHODS: Longitudinal analysis using medical and pharmacy
claims data from a large state employer over a 2-year period
(baseline May 1, 2001—April 30, 2002; follow-up May 1,
2002—April 30, 2003). Continuously eligible subjects <65 years
old at the end of the study period were selected. The total cost
Predictive Resource Index from the Johns Hopkins ACG System
Version 6.0 was used to predict inﬂation-adjusted follow-up year
total costs per member (medical plus pharmacy) using baseline
demographic and diagnosis information, with and without
including total pharmacy cost data. Results were compared to
actual follow-up year total costs by grouping actual and pre-
dicted costs ($0; $1–$1,000; $1,001–$5,000; $5,001–$10,000;
>$10,000) and comparing the positive predictive value (PPV)
within each cost grouping. Sensitivity and speciﬁcity were also
individually examined. Analyses were additionally conducted
within disease-speciﬁc subgroups, including diabetes, depression,
asthma, and cardiovascular disease. RESULTS: In the baseline
year, approximately 70% and 75% of the 344,834 included sub-
jects used medical and pharmacy services, respectively. Baseline
total cost averaged $2,665 (median: $621) and pharmacy cost
averaged $640 (median: $167). Follow-up mean actual total 
cost was $3193 (median: $748) and mean ACG-PM predicted
costs were $2789 from both models without and with 
pharmacy costs (respective medians: $1638; $1635). Including
pharmacy costs in the model increased the PPV, especially at
high-cost groups: 40.77% to 48.74% (+7.97%) at >$10,000 and
23.97% to 28.18% (+4.21%) at $5,001–$10,000. PPVs were
higher within disease-speciﬁc subgroups and increased with
inclusion of pharmacy costs, with the highest PPVs in the depres-
sion cohort (>10,000: 51.31% (without pharmacy costs) to
58.92% (with pharmacy costs); $5,000-$10,000: 29.92% to
35.31%). CONCLUSIONS: Addition of pharmacy cost data 
to the ACG-PM results in more accurate identiﬁcation of future
total health care costs, especially among high-cost members.
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OBJECTIVES: Washington Panel and UK NICE guidelines
propose that the health affects of patient care on their carers
should be included within the denominator of cost-utility analy-
ses. The impact of patient disability on carers has been demon-
strated by directly measuring the quality of life (QoL) of carers
in speciﬁc patient populations with substantial informal care
needs. However, it is possible that a general relationship between
patient and carer quality of life exists, whereby any improve-
ments in patient QoL are mirrored by improvements in carer
QoL. If such a general relationship does exist, any intervention
that generates additional patient quality adjusted life years
(QALYs) will also generate additional carer QALYs. We investi-
gated whether a general relationship between patient and carer
QoL exists using the Health Outcomes Data Repository
(HODaR). METHODS: Using a sample of 15,113 patients we
estimated the relationship between utility and time away from
normal activities for patients, along with the relationship
between patient utility and carer time spent helping patients. For
any given patient utility we can then predict carer time, and
assuming that this has the same impact on well-being as time
away form normal activities has on patients, predict carer utility.
RESULTS: A simple relationship shows that a reduction in utility
of 0.10 was associated with a 0.017 reduction in carer utility
(i.e. QALY gains are increased by 17%). More complex models
looked at the type of disabilities that were associated with greater
or lesser carer effects. CONCLUSION: This work is preliminary,
but points to the possibility of a general relationship between
patient and carer QoL. Additional research is required that
directly measures carer QoL, and identiﬁes whether it was inﬂu-
enced by the general health of the patient or speciﬁc disabilities.
Any widespread effect may have a profound effect on the future
funding decisions.
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OBJECTIVE: To study the effects of improvement in patients’
health on the welfare of their family members and its implica-
tions to medical cost-effectiveness analysis. METHODS: We use
a theoretical model based on a family utility function with altru-
istic linkages to show that there can be direct and indirect welfare
effects to all family members. Using the SEER-Medicare data-
base we test the predictions of our model by studying treatment
choice of prostate cancer patient by age and marital statuses.
RESULTS: The theoretical model suggests that a health inter-
vention has both the traditional direct effects on the patient, and
spillover effects on the family. In a 2-person household, the
spillover effect is ﬁrst the average change in QOL of the spouse
multiplied second by the probability that the patient remains
married at all future time periods. The magnitude and direction
of the ﬁrst component is based on a tradeoff between positive
spillover effects due to treatment related survival and QOL 
beneﬁts to the patient and negative spillover effects due to side
effects of treatment. Treatments for clinically localized prostate
cancer present such tradeoffs with positive spillover effects to the
spouse dominating for patients aged 60–70 years and vice versa
for older patients. Since the second component differs between
married and unmarried patients between these two age ranges,
we are able to test our theory by studying differences in treat-
ment choice between married and unmarried patients by age.
After controlling for clinical characteristics and patient demo-
graphics, we ﬁnd that the proportion of married patients 60–70
years of age who choose aggressive treatments for prostate
cancer is signiﬁcantly greater than the corresponding proportion
of unmarried patients. This pattern reverses at higher ages of the
patient. CONCLUSIONS: We conclude that cost-effectiveness
analyses may better reﬂect the full costs and beneﬁts of medical
interventions if they incorporate these family effects.
